Biotechnology & Medical Research

Trevena announces positive results from phase 2b study of TRV130 in Acute Postoperative Pain

Trevena:Announces positive results from phase 2b study of trv130 in acute postoperative pain.Says superior safety and tolerability profile of trv130 compared to morphine.Says novel mu-opioid receptor modulator trv130 achieved primary endpoint.Says trv130 demonstrated statistically significant pain...

4:01pm EDT

NeuroSearch maintains FY 2015 outlook

NeuroSearch A/S:Expects in FY 2015 an operating loss in range of 7 million - 9 million Danish crowns.

4:50am EDT

Diamyd Medical AB licenses candidate drug for diabetes and gluten intolerance

Diamyd Medical AB:Says that it has entered into an license agreement for using the gluten protein gliadin for the treatment and prevention of type 1 diabetes.Diamyd Medical aims at evaluating combination regimens of gliadin with compounds and antigens, such as for example GABA and GAD, for shutting...

2:30am EDT

Mergers & Acquisitions

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00
Provider : Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.